{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:17:41Z","timestamp":1791220661510,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"19","license":[{"start":{"date-parts":[[2011,1,17]],"date-time":"2011-01-17T00:00:00Z","timestamp":1295222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,1,17]],"date-time":"2011-01-17T00:00:00Z","timestamp":1295222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2011,5,12]]},"DOI":"10.1038\/onc.2010.599","type":"journal-article","created":{"date-parts":[[2011,5,12]],"date-time":"2011-05-12T04:06:31Z","timestamp":1305173191000},"page":"2275-2281","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Histone deacetylase inhibitors prime medulloblastoma cells for chemotherapy-induced apoptosis by enhancing p53-dependent Bax activation"],"prefix":"10.1038","volume":"30","author":[{"given":"S","family":"H\u00e4cker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Karl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Mader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Cristofanon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Schweitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Krauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Rutkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K-M","family":"Debatin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Fulda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,1,17]]},"reference":[{"key":"BFonc2010599_CR1","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/sj.onc.1210220","volume":"26","author":"JM Adams","year":"2007","unstructured":"Adams JM, Cory S . (2007). The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26: 1324\u20131337.","journal-title":"Oncogene"},{"key":"BFonc2010599_CR2","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nrd2133","volume":"5","author":"JE Bolden","year":"2006","unstructured":"Bolden JE, Peart MJ, Johnstone RW . (2006). Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769\u2013784.","journal-title":"Nat Rev Drug Discov"},{"key":"BFonc2010599_CR3","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1126\/science.1068999","volume":"296","author":"TR Brummelkamp","year":"2002","unstructured":"Brummelkamp TR, Bernards R, Agami R . (2002). A system for stable expression of short interfering RNAs in mammalian cells. Science 296: 550\u2013553.","journal-title":"Science"},{"key":"BFonc2010599_CR4","doi-asserted-by":"publisher","first-page":"5318","DOI":"10.1158\/0008-5472.CAN-06-3996","volume":"67","author":"CS Chen","year":"2007","unstructured":"Chen CS, Wang YC, Yang HC, Huang PH, Kulp SK, Yang CC et al. (2007). Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. Cancer Res 67: 5318\u20135327.","journal-title":"Cancer Res"},{"key":"BFonc2010599_CR5","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S1097-2765(04)00094-2","volume":"13","author":"HY Cohen","year":"2004","unstructured":"Cohen HY, Lavu S, Bitterman KJ, Hekking B, Imahiyerobo TA, Miller C et al. (2004). Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol Cell 13: 627\u2013638.","journal-title":"Mol Cell"},{"key":"BFonc2010599_CR6","doi-asserted-by":"publisher","first-page":"4798","DOI":"10.1038\/sj.onc.1209608","volume":"25","author":"S Fulda","year":"2006","unstructured":"Fulda S, Debatin KM . (2006). Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25: 4798\u20134811.","journal-title":"Oncogene"},{"key":"BFonc2010599_CR7","doi-asserted-by":"publisher","first-page":"5865","DOI":"10.1038\/sj.onc.1204750","volume":"20","author":"S Fulda","year":"2001","unstructured":"Fulda S, Kufer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin KM . (2001). Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 20: 5865\u20135877.","journal-title":"Oncogene"},{"key":"BFonc2010599_CR8","doi-asserted-by":"publisher","first-page":"10502","DOI":"10.1158\/0008-5472.CAN-05-0866","volume":"65","author":"S Giagkousiklidis","year":"2005","unstructured":"Giagkousiklidis S, Vogler M, Westhoff MA, Kasperczyk H, Debatin KM, Fulda S . (2005). Sensitization for gamma-irradiation-induced apoptosis by second mitochondria-derived activator of caspase. Cancer Res 65: 10502\u201310513.","journal-title":"Cancer Res"},{"key":"BFonc2010599_CR9","doi-asserted-by":"publisher","first-page":"4604","DOI":"10.1038\/sj.onc.1203816","volume":"19","author":"MA Grotzer","year":"2000","unstructured":"Grotzer MA, Eggert A, Zuzak TJ, Janss AJ, Marwaha S, Wiewrodt BR et al. (2000). Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression. Oncogene 19: 4604\u20134610.","journal-title":"Oncogene"},{"key":"BFonc2010599_CR10","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1038\/onc.2009.161","volume":"28","author":"S Hacker","year":"2009","unstructured":"Hacker S, Dittrich A, Mohr A, Schweitzer T, Rutkowski S, Krauss J et al. (2009). Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8. Oncogene 28: 3097\u20133110.","journal-title":"Oncogene"},{"key":"BFonc2010599_CR11","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.biocel.2007.02.009","volume":"39","author":"H Hess-Stumpp","year":"2007","unstructured":"Hess-Stumpp H, Bracker TU, Henderson D, Politz O . (2007). MS-275, a potent orally available inhibitor of histone deacetylases: the development of an anticancer agent. Int J Biochem Cell Biol 39: 1388\u20131405.","journal-title":"Int J Biochem Cell Biol"},{"key":"BFonc2010599_CR12","first-page":"6108","volume":"62","author":"J Jaboin","year":"2002","unstructured":"Jaboin J, Wild J, Hamidi H, Khanna C, Kim CJ, Robey R et al. (2002). MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res 62: 6108\u20136115.","journal-title":"Cancer Res"},{"key":"BFonc2010599_CR13","doi-asserted-by":"publisher","first-page":"4239","DOI":"10.1111\/j.1582-4934.2009.00888.x","volume":"13","author":"S Karl","year":"2009","unstructured":"Karl S, Pritschow Y, Volcic M, H\u00e4cker S, Baumann B, Wiesm\u00fcller L et al. (2009). Identification of a novel pro-apoptotic function of NF-kappaB in the DNA damage response. J Cell Mol Med 13: 4239\u20134256.","journal-title":"J Cell Mol Med"},{"key":"BFonc2010599_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/jnen\/61.3.215","volume":"61","author":"P Kleihues","year":"2002","unstructured":"Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC et al. (2002). The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61: 215\u2013225; discussion 226\u2013229.","journal-title":"J Neuropathol Exp Neurol"},{"key":"BFonc2010599_CR15","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/sj.bjc.6601510","volume":"90","author":"R Kuefer","year":"2004","unstructured":"Kuefer R, Hofer MD, Altug V, Zorn C, Genze F, Kunzi-Rapp K et al. (2004). Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. Br J Cancer 90: 535\u2013541.","journal-title":"Br J Cancer"},{"key":"BFonc2010599_CR16","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1097\/CCO.0b013e3283127095","volume":"20","author":"MJ Lee","year":"2008","unstructured":"Lee MJ, Kim YS, Kummar S, Giaccone G, Trepel JB . (2008). Histone deacetylase inhibitors in cancer therapy. Curr Opin Oncol 20: 639\u2013649.","journal-title":"Curr Opin Oncol"},{"key":"BFonc2010599_CR17","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1158\/1078-0432.CCR-07-2072","volume":"14","author":"A Rossi","year":"2008","unstructured":"Rossi A, Caracciolo V, Russo G, Reiss K, Giordano A . (2008). Medulloblastoma: from molecular pathology to therapy. Clin Cancer Res 14: 971\u2013976.","journal-title":"Clin Cancer Res"},{"key":"BFonc2010599_CR18","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1158\/1078-0432.CCR-06-1779","volume":"13","author":"S Rutkowski","year":"2007","unstructured":"Rutkowski S, von Bueren A, von Hoff K, Hartmann W, Shalaby T, Deinlein F et al. (2007). Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT\u201991. Clin Cancer Res 13: 2651\u20132657.","journal-title":"Clin Cancer Res"},{"key":"BFonc2010599_CR19","doi-asserted-by":"publisher","first-page":"4842","DOI":"10.1073\/pnas.0408351102","volume":"102","author":"C Subramanian","year":"2005","unstructured":"Subramanian C, Opipari Jr AW, Bian X, Castle VP, Kwok RP . (2005). Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 102: 4842\u20134847.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2010599_CR20","doi-asserted-by":"publisher","first-page":"20197","DOI":"10.1074\/jbc.M109.026096","volume":"284","author":"SM Sykes","year":"2009","unstructured":"Sykes SM, Stanek TJ, Frank A, Murphy ME, McMahon SB . (2009). Acetylation of the DNA binding domain regulates transcription-independent apoptosis by p53. J Biol Chem 284: 20197\u201320205.","journal-title":"J Biol Chem"},{"key":"BFonc2010599_CR21","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1200\/JCO.2009.23.5952","volume":"28","author":"U Tabori","year":"2010","unstructured":"Tabori U, Baskin B, Shago M, Alon N, Taylor MD, Ray PN et al. (2010). Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. J Clin Oncol 28: 1345\u20131350.","journal-title":"J Clin Oncol"},{"key":"BFonc2010599_CR22","doi-asserted-by":"publisher","first-page":"7956","DOI":"10.1158\/0008-5472.CAN-08-1296","volume":"68","author":"M Vogler","year":"2008","unstructured":"Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M et al. (2008). Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. Cancer Res 68: 7956\u20137965.","journal-title":"Cancer Res"},{"key":"BFonc2010599_CR23","doi-asserted-by":"publisher","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","volume":"26","author":"WS Xu","year":"2007","unstructured":"Xu WS, Parmigiani RB, Marks PA . (2007). Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26: 5541\u20135552.","journal-title":"Oncogene"},{"key":"BFonc2010599_CR24","doi-asserted-by":"publisher","first-page":"11171","DOI":"10.1074\/jbc.M809268200","volume":"284","author":"H Yamaguchi","year":"2009","unstructured":"Yamaguchi H, Woods NT, Piluso LG, Lee HH, Chen J, Bhalla KN et al. (2009). p53 acetylation is crucial for its transcription-independent proapoptotic functions. J Biol Chem 284: 11171\u201311183.","journal-title":"J Biol Chem"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/onc2010599.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2010599","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2010599.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T17:19:47Z","timestamp":1647883187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2010599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,17]]},"references-count":24,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2011,5,12]]}},"alternative-id":["BFonc2010599"],"URL":"https:\/\/doi.org\/10.1038\/onc.2010.599","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,17]]},"assertion":[{"value":"23 February 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2010","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2010","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}